Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Nicole Bourgault who wrote (9724)	2/23/1999 1:35:00 PM
From: Jules	Respond to of 56532

Techne Acquires Cistron Biotechnology's Research Reagents Business and Exclusive Sublicense to Certain Interleukin 1 Beta Patents for the Research Market Jump to first matched term MINNEAPOLIS, Feb. 23 /PRNewswire/ -- Techne Corporation (Nasdaq: TECH) and Cistron Biotechnology, Inc. (OTC Bulletin Board: CIST) announced today that through TECHNE's subsidiary, Research and Diagnostics Systems, Inc. (R&D Systems), TECHNE has purchased from Cistron its research reagents business and exclusive research market rights to Interleukin 1 beta (IL-1B) antibody and immunoassay patents. Cistron will retain diagnostic and therapeutic marketing rights on the IL-1B patents. The effective date of the acquisition is April 1, 1999. R&D Systems paid $750,000 cash for Cistron's research reagents business and IL-1B research market patent rights. In addition, royalties will be paid on the net sales of IL-1B proteins, antibodies and immunoassays by TECHNE and its subsidiaries for the life of the patents. Cistron's research reagent sales for their fiscal year ended June 30,1998 were approximately $550,000. Thomas E. Oland, President of TECHNE said, "We have had a working relationship with Cistron for a number of years and we were very pleased that they came to us when they decided to withdraw from the research reagents market place. We believe we are the leaders in the cytokine research reagents market and that we will be able to maximize Cistron's royalty stream on sales of IL-1B." Bruce C. Galton, Chairman and CEO of Cistron said, "Cistron is concentrating on the research and development of the therapeutic and diagnostic applications of our technologies rather than continue the production and sale of research reagents. R&D Systems was a natural choice to work with for the research product market due to their scientific strength and marketing expertise." Cistron's primary product area is immune response regulators known as lymphokines. The company is developing therapeutic and diagnostic applications of its technology for cancer, arthritis and other auto immune diseases. TECHNE Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe Ltd. of Abingdon England. R&D Systems is a specialty manufacturer of biological products and R&D Systems Europe is a distributor of biotechnology products.

To: Nicole Bourgault who wrote (9724)	2/23/1999 2:05:00 PM
From: snerd	Read Replies (1) \| Respond to of 56532

TAVA... News out on deal with U. S. Post Office marketguide2.newsalert.com Could be a gapper in the morning, but not sure. Ya may want to watch it. I got me 200 shares. ; ) Snerd